Geron Reports Strong Q1 RYTELO Revenue Growth, Significantly Narrows Net Loss
Summary
Geron Corporation reported strong first-quarter 2026 financial results, achieving $51.8 million in RYTELO net product revenue, an 8% increase from the prior quarter. The company significantly narrowed its net loss to $3.6 million, or $0.01 per share, a substantial improvement from $19.8 million in Q1 2025. This positive financial performance was complemented by key business achievements, including the inclusion of imetelstat (RYTELO) in the National Comprehensive Cancer Network® (NCCN®) Chemotherapy Order Templates, a significant step for product adoption. Geron also reiterated its 2026 revenue and operating expense guidance and ended the quarter with $341 million in cash. These results indicate strong commercial execution and improved financial discipline, which are critical for a commercial-stage biopharmaceutical company. Investors will be watching for continued RYTELO demand growth and updates on European commercial plans and investigator-sponsored trials.
At the time of this announcement, GERN was trading at $1.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $1.04 to $2.01. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.